Abbott(ABT) - 2025 Q3 - Quarterly Results

News Release & Highlights CEO Statement Robert B. Ford, Chairman and CEO, highlighted consistent, high-quality performance in Q3 2025, attributing it to a differentiated product pipeline that positions Abbott for durable long-term value to shareholders - Robert B. Ford, chairman and chief executive officer, Abbott, stated: 'Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance. Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders'[2] Key Financial Highlights (3Q25 & YTD) Abbott reported strong financial results for Q3 2025, with significant sales growth and adjusted diluted EPS, alongside positive year-to-date performance, demonstrating consistent execution Key Financial Highlights (3Q25 & YTD) | Metric | 3Q25 Reported | 3Q25 Organic (excl. COVID-19) | YTD Reported | YTD Organic (excl. COVID-19) | | :----- | :------------ | :---------------------------- | :----------- | :--------------------------- | | Sales Growth | 6.9% | 7.5% | 6.1% | 7.7% | | GAAP Diluted EPS | $0.94 | N/A | N/A | N/A | | Adjusted Diluted EPS | $1.30 | N/A | N/A | N/A | | Reported Operating Margin | 18.1% | N/A | N/A | N/A | | Adjusted Operating Margin | 23.0% (40 bps increase) | N/A | N/A | N/A | Recent Product & Regulatory Milestones Abbott achieved key regulatory approvals and received supportive treatment guidelines for its innovative medical devices, enhancing its market position in cardiovascular health - Regulatory approval in Japan for TriClip®, a first-of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation[2] - CE Mark received for an expanded indication for the Navitor® transcatheter aortic valve implantation (TAVI) system to treat symptomatic, severe aortic stenosis patients at low or intermediate risk for open-heart surgery[2] - New treatment guidelines issued at the European Society of Cardiology (ESC) Congress provide additional support for the use of MitraClip® and TriClip® in treating valvular heart disease[2] Third-Quarter Business Overview Overall Sales Performance (3Q25 & 9M25) Abbott's overall sales demonstrated solid growth in Q3 and year-to-date 2025, particularly when excluding the declining impact of COVID-19 testing sales, with organic growth being a key metric for performance assessment - Management measures sales growth rates on an organic basis, excluding foreign exchange impact and the discontinuation of the ZonePerfect® product line, to understand core underlying business performance[3] Total Company Sales (3Q25 vs 3Q24) | Metric | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | | :----- | :------------ | :-------- | :---------- | :------------------------ | :-------------- | | Total reported sales ($M) | 11,369 | 2,153 | 2,253 | 1,511 | 5,448 | | Total reported % Change | 6.9% | 4.2% | (6.6)% | 7.5% | 14.8% | | Organic % Change | 5.5% | 4.0% | (7.8)% | 7.1% | 12.5% | | Organic (excl. COVID-19 tests) % Change | 7.5% | 4.0% | 0.4% | 7.1% | 12.5% | Total Company Sales (9M25 vs 9M24) | Metric | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | | :----- | :------------ | :-------- | :---------- | :------------------------ | :-------------- | | Total reported sales ($M) | 32,869 | 6,511 | 6,480 | 4,154 | 15,712 | | Total reported % Change | 6.1% | 3.6% | (5.0)% | 5.8% | 12.8% | | Organic % Change | 6.4% | 4.7% | (4.8)% | 7.5% | 12.4% | | Organic (excl. COVID-19 tests) % Change | 7.7% | 4.7% | 0.6% | 7.5% | 12.4% | Nutrition Segment Performance The Nutrition segment achieved reported sales growth of 4.2% and organic growth of 4.0% in Q3 2025, primarily driven by strong performance in Adult Nutrition, particularly from Ensure® and Glucerna® brands Nutrition Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Pediatric | Adult | | :------------------------ | :---- | :-------- | :---- | | U.S. | 888 | 520 | 368 | | International | 1,265 | 457 | 808 | | Total reported | 2,153 | 977 | 1,176 | | % Change vs. 3Q24 | | | | | U.S. | (6.5) | (8.4) | (3.8) | | International | 13.3 | 17.9 | 10.9 | | Total reported | 4.2 | 2.3 | 5.8 | | Impact of foreign exchange | 0.2 | (0.1) | 0.4 | | Organic | 4.0 | 2.4 | 5.4 | - Growth in the quarter was led by Adult Nutrition, with sales increasing 5.8 percent reported and 5.4 percent organic, driven by strong growth of Ensure® and Glucerna®[9] Nutrition Sales (9M25 vs 9M24) | Sales 9M25 ($ in millions) | Total | Pediatric | Adult | | :------------------------ | :---- | :-------- | :---- | | U.S. | 2,800 | 1,695 | 1,105 | | International | 3,711 | 1,377 | 2,334 | | Total reported | 6,511 | 3,072 | 3,439 | | % Change vs. 9M24 | | | | | U.S. | 1.4 | 3.0 | (0.9) | | International | 5.3 | — | 8.8 | | Total reported | 3.6 | 1.6 | 5.5 | | Impact of foreign exchange | (0.9) | (0.9) | (0.9) | | Impact of business exit* | (0.2) | — | (0.4) | | Organic | 4.7 | 2.5 | 6.8 | Diagnostics Segment Performance Global Diagnostics sales decreased in Q3 2025 on a reported and organic basis, primarily due to a significant decline in COVID-19 testing-related sales. Excluding COVID-19 tests, organic sales showed slight growth, with Core Laboratory Diagnostics experiencing growth despite challenging market conditions in China Diagnostics Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Core Laboratory | Molecular | Point of Care | Rapid Diagnostics | | :------------------------ | :---- | :-------------- | :-------- | :------------ | :---------------- | | U.S. | 886 | 366 | 36 | 111 | 373 | | International | 1,367 | 998 | 95 | 47 | 227 | | Total reported | 2,253 | 1,364 | 131 | 158 | 600 | | % Change vs. 3Q24 | | | | | | | U.S. | (14.1) | 10.4 | (1.5) | 7.9 | (33.5) | | International | (1.0) | 1.6 | 4.3 | 8.9 | (14.2) | | Total reported | (6.6) | 3.8 | 2.6 | 8.2 | (27.3) | | Impact of foreign exchange | 1.2 | 1.6 | 1.8 | 0.4 | 0.4 | | Organic | (7.8) | 2.2 | 0.8 | 7.8 | (27.7) | | Organic (excluding COVID-19 tests) | 0.4 | N/A | N/A | N/A | N/A | - COVID-19 testing-related sales were $69 million in Q3 2025, a significant decrease from $265 million in Q3 2024[10] - Core Laboratory Diagnostics sales increased 3.8 percent reported and 2.2 percent organic, despite challenging market conditions in China, including volume-based procurement programs[11] Established Pharmaceuticals Segment Performance Established Pharmaceuticals sales increased 7.5% on a reported basis and 7.1% organically in Q3 2025, primarily driven by double-digit organic growth in Key Emerging Markets across Asia, Latin America, and the Middle East Established Pharmaceuticals Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Key Emerging Markets | Other | | :------------------------ | :---- | :------------------- | :---- | | International | 1,511 | 1,097 | 414 | | Total reported | 1,511 | 1,097 | 414 | | % Change vs. 3Q24 | | | | | International | 7.5 | 10.3 | 0.6 | | Total reported | 7.5 | 10.3 | 0.6 | | Impact of foreign exchange | 0.4 | (0.8) | 3.1 | | Organic | 7.1 | 11.1 | (2.5) | - Sales in Key Emerging Markets increased 10.3 percent reported and 11.1 percent organic, driven by double-digit growth in several countries across Asia, Latin America, and the Middle East[14] Established Pharmaceuticals Sales (9M25 vs 9M24) | Sales 9M25 ($ in millions) | Total | Key Emerging Markets | Other | | :------------------------ | :---- | :------------------- | :---- | | International | 4,154 | 3,121 | 1,033 | | Total reported | 4,154 | 3,121 | 1,033 | | % Change vs. 9M24 | | | | | International | 5.8 | 7.3 | 1.7 | | Total reported | 5.8 | 7.3 | 1.7 | | Impact of foreign exchange | (1.7) | (2.4) | 0.5 | | Organic | 7.5 | 9.7 | 1.2 | Medical Devices Segment Performance The Medical Devices segment delivered strong performance in Q3 2025, with reported sales increasing 14.8% and organic sales growing 12.5%, driven by double-digit growth across several key areas including Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart Medical Devices Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Rhythm Management | Electrophysiology | Heart Failure | Vascular | Structural Heart | Neuromodulation | Diabetes Care | | :------------------------ | :---- | :---------------- | :---------------- | :------------ | :------- | :--------------- | :-------------- | :------------ | | U.S. | 2,521 | 350 | 322 | 280 | 280 | 297 | 196 | 796 | | International | 2,927 | 336 | 383 | 86 | 465 | 338 | 58 | 1,261 | | Total reported | 5,448 | 686 | 705 | 366 | 745 | 635 | 254 | 2,057 | | % Change vs. 3Q24 | | | | | | | | | | U.S. | 13.8 | 21.1 | 13.2 | 10.7 | 8.5 | 10.1 | 3.3 | 18.4 | | International | 15.6 | 9.3 | 17.6 | 22.6 | 5.5 | 16.9 | 24.9 | 19.9 | | Total reported | 14.8 | 15.0 | 15.6 | 13.3 | 6.6 | 13.6 | 7.6 | 19.3 | | Impact of foreign exchange | 2.3 | 2.0 | 1.9 | 1.2 | 1.9 | 2.3 | 0.8 | 3.1 | | Organic | 12.5 | 13.0 | 13.7 | 12.1 | 4.7 | 11.3 | 6.8 | 16.2 | - Sales growth in Q3 was led by double-digit growth in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart[17] - Diabetes Care sales of continuous glucose monitors reached $2.0 billion, growing 20.5 percent reported and 17.2 percent organic[17] Abbott's Financial Guidance & Shareholder Information Full-Year 2025 Financial Guidance Abbott reaffirmed its full-year 2025 organic sales growth guidance and narrowed its adjusted diluted EPS guidance range, reflecting anticipated double-digit growth - Abbott reaffirms full-year 2025 organic sales growth guidance of 7.5% to 8.0% (excluding COVID-19 testing-related sales) or 6.0% to 7.0% (including COVID-19 testing-related sales)[19] - Abbott reaffirms the midpoint of full-year 2025 adjusted diluted EPS guidance and narrows the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint[19] Dividend Declaration Abbott declared its 407th consecutive quarterly dividend of $0.59 per share, payable in November 2025, underscoring its long-standing commitment to shareholder returns as a Dividend Aristocrat - On Sept. 19, 2025, Abbott's board of directors declared a quarterly dividend of $0.59 per share[21] - The cash dividend is payable Nov. 17, 2025, to shareholders of record on Oct. 15, 2025[21] - Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index[21] Company Overview Abbott is a global healthcare leader providing life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with 114,000 employees - Abbott is a global healthcare leader with a portfolio of life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines[22] - The company has 114,000 colleagues serving people in more than 160 countries[22] Financial Statements & Non-GAAP Reconciliations Condensed Consolidated Statement of Earnings The condensed consolidated statements of earnings for Q3 and 9M 2025 show net sales growth and changes in operating earnings, net earnings, and diluted EPS compared to the prior year, both on a GAAP and adjusted basis Condensed Consolidated Statement of Earnings (3Q25 vs 3Q24) | Metric | 3Q25 ($M) | 3Q24 ($M) | % Change | | :----- | :-------- | :-------- | :------- | | Net Sales | $11,369 | $10,635 | 6.9% | | Operating Earnings | $2,057 | $1,859 | 10.6% | | Net Earnings (GAAP) | $1,644 | $1,646 | (0.1)% | | Net Earnings (excl. Specified Items) | $2,278 | $2,119 | 7.5% | | Diluted EPS (GAAP) | $0.94 | $0.94 | — | | Diluted EPS (excl. Specified Items) | $1.30 | $1.21 | 7.4% | Condensed Consolidated Statement of Earnings (9M25 vs 9M24) | Metric | 9M25 ($M) | 9M24 ($M) | % Change | | :----- | :-------- | :-------- | :------- | | Net Sales | $32,869 | $30,976 | 6.1% | | Operating Earnings | $5,802 | $4,914 | 18.1% | | Net Earnings (GAAP) | $4,748 | $4,173 | 13.8% | | Net Earnings (excl. Specified Items) | $6,410 | $5,851 | 9.6% | | Diluted EPS (GAAP) | $2.70 | $2.38 | 13.4% | | Diluted EPS (excl. Specified Items) | $3.65 | $3.33 | 9.6% | Non-GAAP Financial Information Reconciliation Abbott provides detailed reconciliations from GAAP to adjusted financial measures for Q3 and 9M 2025 and 2024, primarily adjusting for intangible amortization, restructuring, acquisition-related expenses, and other specified items to present a clearer view of core operational performance Non-GAAP Reconciliation (3Q25) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $420 | $(420) | $0 | | Gross Margin | $5,874 | $470 | $6,344 | | R&D | $766 | $(36) | $730 | | SG&A | $3,051 | $(47) | $3,004 | | Other (income) expense, net | $(150) | $5 | $(145) | | Earnings before taxes | $2,180 | $548 | $2,728 | | Taxes on Earnings | $536 | $(86) | $450 | | Net Earnings | $1,644 | $634 | $2,278 | | Diluted Earnings per Share | $0.94 | $0.36 | $1.30 | Non-GAAP Reconciliation (3Q24) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $470 | $(470) | $0 | | Gross Margin | $5,467 | $516 | $5,983 | | R&D | $713 | $(19) | $694 | | SG&A | $2,895 | $(5) | $2,890 | | Other (income) expense, net | $(121) | $(12) | $(133) | | Earnings before taxes | $1,940 | $552 | $2,492 | | Taxes on Earnings | $294 | $79 | $373 | | Net Earnings | $1,646 | $473 | $2,119 | | Diluted Earnings per Share | $0.94 | $0.27 | $1.21 | Non-GAAP Reconciliation (9M25) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $1,260 | $(1,260) | $0 | | Gross Margin | $17,212 | $1,396 | $18,608 | | R&D | $2,207 | $(83) | $2,124 | | SG&A | $9,203 | $(58) | $9,145 | | Other (income) expense, net | $(414) | $(31) | $(445) | | Earnings before taxes | $6,108 | $1,568 | $7,676 | | Taxes on Earnings | $1,360 | $(94) | $1,266 | | Net Earnings | $4,748 | $1,662 | $6,410 | | Diluted Earnings per Share | $2.70 | $0.95 | $3.65 | Tax Rate Reconciliation Abbott reconciled its GAAP tax rates to adjusted tax rates for Q3 and 9M 2025 and 2024, showing the impact of specified items and certain tax adjustments on the effective tax rate Tax Rate Reconciliation (3Q25 vs 3Q24) | Metric | 3Q25 GAAP Tax Rate | 3Q25 Adjusted Tax Rate | 3Q24 GAAP Tax Rate | 3Q24 Adjusted Tax Rate | | :----- | :----------------- | :--------------------- | :----------------- | :--------------------- | | Tax Rate | 24.6% | 16.5% | 15.2% | 15.0% | Tax Rate Reconciliation (9M25 vs 9M24) | Metric | 9M25 GAAP Tax Rate | 9M25 Adjusted Tax Rate | 9M24 GAAP Tax Rate | 9M24 Adjusted Tax Rate | | :----- | :----------------- | :--------------------- | :----------------- | :--------------------- | | Tax Rate | 22.3% | 16.5% | 16.3% | 15.0% | Non-GAAP Revenue Reconciliation Abbott provided a non-GAAP revenue reconciliation for the nine months ended September 30, 2025 and 2024, detailing the impact of discontinuing the ZonePerfect® product line in the Nutrition business on reported and adjusted revenue figures Non-GAAP Revenue Reconciliation (9M25 vs 9M24) | Metric | 9M25 Abbott Reported ($M) | 9M24 Abbott Reported ($M) | Impact from business exit (a) ($M) | 9M24 Adjusted Revenue ($M) | % Change vs. 9M24 Reported | % Change vs. 9M24 Adjusted | Organic % Change | | :----- | :------------------------ | :------------------------ | :--------------------------------- | :------------------------- | :------------------------- | :------------------------- | :--------------- | | Total Company | 32,869 | 30,976 | (13) | 30,963 | 6.1% | 6.1% | 6.4% | | Total Nutrition | 6,511 | 6,284 | (13) | 6,271 | 3.6% | 3.8% | 4.7% | | Adult Nutrition | 3,439 | 3,261 | (13) | 3,248 | 5.5% | 5.9% | 6.8% | - The business exit impact reflects the discontinuation of the ZonePerfect® product line in the Nutrition business, initiated in March 2024[47] Details of Specified Items This section provides a detailed breakdown of the specific items that are excluded from GAAP financial measures to arrive at adjusted (non-GAAP) figures for the third quarter and nine months ended September 30, 2025 and 2024. These items primarily include intangible amortization, restructuring and cost reduction initiatives, acquisition/divestiture-related expenses, and other adjustments - For 3Q25, specified items include $420 million for intangible amortization and $128 million for restructuring, acquisition costs, and other net expenses[38][49] - For 3Q24, specified items include $470 million for intangible amortization and $82 million for intangible impairment, acquisitions, a divestiture, and other net expenses[39][52] - For 9M25, specified items include $1.260 billion for intangible amortization and $308 million for restructuring, acquisitions, investment impairment charges, and other net expenses[42][55] - For 9M24, specified items include $1.413 billion for intangible amortization and $487 million for restructuring, acquisitions, a divestiture, and other net expenses[43][58]